Roche says flexible pricing ready for cancer, not MS drugs

ZURICH, Nov 7 (Reuters) - The spotlight on finding a cancer

cure has spurred improvements in systems to collect and analyze

oncology data, but efforts to track patients with other diseases

lag behind, Roche pricing head Jens Grueger said.

Read more